Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

The emergence of immunotherapy has dramatically changed how non–small cell lung cancer is treated, and longer survival is now possible for some patients, even those with advanced disease. Although some patients achieve durable responses to checkpoint blockade, not all experience such benefits, and s...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 126; no. 2; pp. 260 - 270
Main Authors:	Bodor, J. Nicholas, Boumber, Yanis, Borghaei, Hossein
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 15.01.2020
Subjects:	Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - genetics B7-H1 Antigen - immunology B7-H1 Antigen - metabolism Biomarkers Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - immunology Drug Monitoring - methods Gene expression Gene Expression Profiling Genotypes Humans Immune checkpoint inhibitors Immunohistochemistry Immunotherapy Liquid Biopsy - methods Lung - drug effects Lung - immunology Lung - pathology Lung cancer Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Lymphocytes Mutation Mutation Rate Non-small cell lung carcinoma non–small‐cell lung cancer Oncology PD-L1 protein programmed death ligand 1 (PD‐L1) Small cell lung carcinoma Treatment Outcome Tumor Microenvironment - drug effects Tumor Microenvironment - immunology tumor mutational burden (TMB) Tumors programmed death ligand 1 (PD-L1) tumor mutational burden (TMB) biomarkers immunotherapy non-small-cell lung cancer
ISSN:	0008-543X, 1097-0142, 1097-0142
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!